

GENERAL INFORMATION

VENUE

OBA (Openbare Bibliotheek Amsterdam)
Amsterdam Public Library
Oosterdoksade 143
1011 DL Amsterdam

REGISTRATION

Registration fee:
Industry delegates € 200,--
Physicians/Academics € 100,--
Phd students/Fellows € 50,--

This fee includes lunch, coffee, tea

Registration on-line only: www.epgs.nl
The number of seats is limited, first come first serve.

ACCREDITATION

Accreditation has been requested.
All participants will receive a certificate of attendance.

INFORMATION

For further information please contact:

European Postgraduate Gastro-surgical
School (EPGS)
Meibergdreef 9
1105 AZ Amsterdam

Tel: 020-566 3926/6468
E-mail: epgs@amc.nl




Registrations: www.epgs.nl

2nd TDM Symposium

Contemporary use of therapeutic drug monitoring of biologics in chronic diseases: From point of care to personalised medicine

Openbare Bibliotheek Amsterdam (OBA)
the Amsterdam Public Library
December 7, 2018



Amsterdam UMC

Therapeutic drug monitoring of biologics has moved from a concept to implementation in inflammatory diseases. Sufficient target engagement appears to be of paramount importance, whereas the immunogenicity of the monoclonal antibodies is an additional confounding factor that needs to be addressed. Optimal serum concentrations are the main driver for outcome and personalised medicine.

In this second symposium we will discuss how individualised dosing is being applied successfully in rheumatology, dermatology and gastroenterology. Also, we will discuss the potential of TDM for biologics in oncology. Sanquin and the Amsterdam UMC jointly organise this symposium where we aim to bring together clinicians and pharmacists/clinical pharmacologists with a special interest in PK-PD of biologics. Together with the participants from pharma this will create a forum to exchange ideas, make new connections and learn. We look forward to welcoming you in the public library in the very heart of Amsterdam, The Netherlands.

The steering committee
Annick de Vries, Theo Rispens, Phyllis Spuls, Ron Mathôt, Gertjan Wolbink en Geert D'Haens.

FACULTY

Dr. Omoniyi Adedokun, Janssen Research & Development, Spring House, USA
Drs. Merel L'Ami, Reade, Amsterdam, the Netherlands
Prof. Gijs van den Brink, GSK, London, UK
Prof. Yehuda Chowers, Rambam Hospital, Haifa, Israel
Prof. Ann Gils, University of Leuven, Leuven, Belgium
Prof. Geert D'Haens, Amsterdam UMC, the Netherlands
Dr. Tim Hickling, Pfizer, New York, USA
Prof. Alwin Huitema, UMC Utrecht, the Netherlands
Dr. Peter Irving, Guys and Thomas Hospital, London, UK
Prof. Tore Kvien, University of Oslo, Norway
Prof. Ron Mathôt, Amsterdam UMC, the Netherlands
Dr. Theo Rispens, Sanquin, Amsterdam, the Netherlands
Prof. Catherine Smith, St John's Institute of Dermatology, London, UK
Prof. Phyllis Spuls, Amsterdam UMC, the Netherlands
Drs. Anne Strik, Amsterdam UMC, the Netherlands
Dr. Carolien Versantvoort, EMA, London, UK
Dr. Annick de Vries, Sanquin, Amsterdam, the Netherlands
Dr. Gertjan Wolbink, Sanquin/Reade/ARC, the Netherlands

PROGRAM

09.30-09.55	INTRODUCTORY LECTURE Challenges and cost of biologics: what will the future offer? <i>Gijs van den Brink</i>
09.55-11.10	SESSION 1: DESIGNING OPTIMAL DOSING SCHEDULES <i>Session chairs: Geert D'Haens, Gertjan Wolbink</i>
09.55-10.20	The clinicians view: why are many dosing schedules wrong? <i>Peter Irving</i>
10.20-10.45	The pharmaceutical industry's view <i>Omoniyi Adedokun</i>
10.45-11.10	The regulator's view: 'How much use is in the label?' <i>Carolien Versantvoort</i>
11.10-11.45	COFFEE BREAK
11.45-13.00	SESSION 2: IMMUNOGENICITY- HOW TO PREVENT, HOW TO HANDLE <i>Session chairs: Ann Gils, Theo Rispens</i>
11.45-12.10	Incidence, risk factors and pathophysiology of immunogenicity - not all antibodies are the same <i>Theo Rispens</i>
12.10-12.35	Immunogenicity - the industry's view <i>Tim Hickling</i>
12.35-13.00	Anti-drug antibodies: How to handle, how to prevent? <i>Yehuda Chowers</i>
13.00-14.15	LUNCH

14.15-15.25	SESSION 3: DEEPER UNDERSTANDING OF THE PK OF BIOLOGICS <i>Session chairs: Phyllis Spuls, Ron Mathôt</i>
14.15-14.40	What can we learn from anti-cancer biologics? <i>Alwin Huitema</i>
14.40-15.05	Personalized dosing of biologics in dermatology <i>Catherine Smith</i>
15.05-15.25	Induction versus maintenance dosing: an outdated algorithm? <i>Chairs: Geert D'Haens, Gertjan Wolbink</i> <i>Panel: Yehuda Chowers, Peter Irving, Catherine Smith, Tore Kvien</i>
15.25-15.55	TEA BREAK
15.55-17.25	SESSION 4: BIOLOGICS AND BIOSIMILARS IN THE ERA OF PERSONALIZED MEDICINE <i>Session chairs: Annick de Vries, Peter Irving</i>
15.55-16.20	Point of care assays: challenges and benefits <i>Ann Gils</i>
16.20-16.35	Clinical application of dashboard systems <i>Anne Strik</i>
16.35-16.50	Taper to serum concentration; a way to tackle over-exposure <i>Merel L'Ami</i>
16.50-17.15	Biosimilars: have switch trials become obsolete? <i>Tore Kvien</i>
17.15-17.25	Q&A
17:30	FAREWELL DRINKS